Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Tumor Necrosis Factor (TNF) II"
Deadline for manuscript submissions: 29 February 2020.
Tumor Necrosis Factor (TNF) and its receptors TNFR1 and TNFR2 are the best-characterized members of the TNFSF and TNFRSF superfamilies, which include, to date, 19 ligands and 29 receptors. TNFSF members have in common the ability to promote pro-inflammatory signals, but they might regulate other cellular functions, such as cell-to-cell communication, differentiation, survival, apoptosis, and necroptosis. TNF activates several intracellular signaling pathways, including NF-kB, JNK, apoptosis (caspase 8 activation), and necroptosis (phosphorylation of RIPK1, RIPK3, and MLKL), of which constant balance regulates the opposite cell fates proliferation and death.
TNF, which is mainly produced by macrophages, NK, and Th1 T lymphocytes, plays a central role in innate and adaptive immunity and in chronic inflammatory diseases, such as those of the joints, including rheumatoid arthritis and spondiloarthris, and those of the intestine, namely the inflammatory bowel diseases. Chronic inflammation, including the TNF–TNFR pathway’s activation, is increasingly being recognized as involved in cancer, obesity, diabetes, cardiovascular diseases, and neurodegenerative disorders. Five drugs blocking TNF–TNFR signaling have been approved for the therapy of chronic inflammatory rheumatic and intestinal diseases. However, the number of these drugs and the number of individuals with diseases that might benefit from this type of treatment, are expected to increase greatly in the near future. This Special Issue on “Tumor Necrosis Factor (TNF)” aims to address the biology of the TNF–TNFR pathway and present the newest knowledge on its role in diseases characterized by chronic inflammation and on established and emerging therapies that target TNF signaling.
Prof. Dr. Daniela Basso
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Tumor Necrosis Factor (TNF);
- TNF receptors;
- Metabolic syndrome;
- Anti-TNF agents.